Barclays analyst Saket Kalia raised the firm’s price target on Omada Health (OMDA) to $29 from $28 and keeps an Overweight rating on the shares. The company reported “another beat and raise” quarter, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA: